(Q43755302)

26 November 2017

BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

14 May 2020

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

14 May 2020

Julia Boshuizen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

14 May 2020

6

Richard Elliott

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

14 May 2020

author name string

Yuqiao Shen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

14 May 2020

Farah L Rehman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

14 May 2020

Ying Feng

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

14 May 2020

Ilirjana Bajrami

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

14 May 2020

Bing Wang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

14 May 2020

Leonard E Post

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

14 May 2020

Alan Ashworth

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

14 May 2020

language of work or name

English

0 references

publication date

23 July 2013

1 reference

26 November 2017

Clinical Cancer Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

14 May 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

14 May 2020

page(s)

5003-5015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

14 May 2020

issue

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

14 May 2020

cites work

1 reference

12 December 2020

Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure

1 reference

12 December 2020

A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein

1 reference

12 December 2020

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

1 reference

12 December 2020

Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2

1 reference

12 December 2020

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

12 December 2020

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

12 December 2020

The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.

1 reference

12 December 2020

Poly(ADP-ribose): novel functions for an old molecule

1 reference

12 December 2020

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

12 December 2020

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

1 reference

12 December 2020

DNA repair pathways as targets for cancer therapy

1 reference

12 December 2020

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

1 reference

12 December 2020

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

1 reference

12 December 2020

A syngeneic variance library for functional annotation of human variation: application to BRCA2

1 reference

12 December 2020

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

1 reference

12 December 2020

A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity

1 reference

12 December 2020

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

1 reference

12 December 2020

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

12 December 2020

DNA Damage, Aging, and Cancer

1 reference

12 December 2020

ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors

1 reference

12 December 2020

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

1 reference

12 December 2020

PARP inhibition: PARP1 and beyond

1 reference

12 December 2020

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

12 December 2020

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

1 reference

12 December 2020

Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers

1 reference

12 December 2020

The DNA damage response and cancer therapy

1 reference

12 December 2020

Advances in using PARP inhibitors to treat cancer

1 reference

12 December 2020

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

1 reference

12 December 2020

Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers

1 reference

12 December 2020

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

1 reference

12 December 2020

Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors

1 reference

12 December 2020

10.1158/1078-0432.CCR-13-1391

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485449&resulttype=core&format=json